<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">OJIM</journal-id><journal-title-group><journal-title>Open Journal of Internal Medicine</journal-title></journal-title-group><issn pub-type="epub">2162-5972</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/ojim.2023.134031</article-id><article-id pub-id-type="publisher-id">OJIM-129034</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Prevalence and Factors Associated with HIV Serodiscordance among Infected Couples in the City of Parakou (Benin)
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Sègnon</surname><given-names>Eurydice Elvire Djossou</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Charles</surname><given-names>Sossa</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Georgia</surname><given-names>Barikissou Damien</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Rhonel</surname><given-names>Ahanhanzo-Glèlè</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Ignace</surname><given-names>Tokpanoudé</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Gottfried</surname><given-names>Agballa</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Ariano</surname><given-names>Vigniavo Nouatin</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Ireti</surname><given-names>Nethania Elie Ataïgba</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Eric</surname><given-names>Dettin</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Badirou</surname><given-names>Aguemon</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>Regional Center for Prospective Information and Advice on HIV and STD of Borgou/Alibori, Parakou, Bénin</addr-line></aff><aff id="aff2"><addr-line>Comlan Alfred Quenum Regional Institute of Public Health, University of Abomey-Calavi (UAC), Ouidah, Bénin</addr-line></aff><aff id="aff1"><addr-line>Public Health Unit of the Faculty of Health Sciences (FHS), University of Abomey-Calavi (UAC), Cotonou, Benin</addr-line></aff><aff id="aff4"><addr-line>Institute of Nursing and Obstetrics Training, University of Parakou School of Medicine, Parakou, Bénin</addr-line></aff><aff id="aff5"><addr-line>Internal Medicine Department, Armed Forces Training Hospital—University Hospital, Parakou, Bénin</addr-line></aff><pub-date pub-type="epub"><day>31</day><month>10</month><year>2023</year></pub-date><volume>13</volume><issue>04</issue><fpage>351</fpage><lpage>363</lpage><history><date date-type="received"><day>16,</day>	<month>September</month>	<year>2023</year></date><date date-type="rev-recd"><day>12,</day>	<month>November</month>	<year>2023</year>	</date><date date-type="accepted"><day>15,</day>	<month>November</month>	<year>2023</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Introduction: Achieving the goal of “zero new human immunodeficiency virus (HIV) infections by 2030” requires the elimination of HIV transmission within serodiscordant couples. In Benin, the phenomenon of HIV serodiscordance remains poorly documented. 
  Objective: the aim of this study was to determine the prevalence of HIV serodiscordance and its associated factors among infected couples in the city of Parakou. 
  Study Framework and Method: This was a descriptive cross-sectional study with an analytical focusing on qualitative and quantitative plans. It was carried out on thirty approved sites in the city of Parakou between July and December 2022. We used a non-exhaustive convenience sample of people living with HIV (PLHIV) whose partner’s status was known. Data collection took place in two phases: an interview phase during which sociodemographic, economic, behavioral and marital/social data were collected. The second phase focused on clinical and therapeutic data which were collected from the patients’ personal records. 
  Results: A total of 417 study subjects were recruited. The average age (SD) of the subjects was 38.17 (&#177;10.25) years [37.19 - 39.16]. Females accounted for the largest proportion (79.62%). Most respondents (74.11%) were married. Monogamous unions were the most frequent, involving 67.87% of participants, most of whom (44.60%) had been infected for between 1 and 5 years. Couples in union for less than 10 years were the most numerous (218 people or 52.28%). The respondent was head of household among only 140 respondents (33.57%) of which 84 men (60.00%) and 56 women (40.00%). Female heads of household were mainly divorcees and widows. Around 75% of PLHIV had monthly incomes of less than 50,000F CFA (81.16 USD). Prevalence of HIV serodiscordance was 71.70%. It was 70.91% [65.54% - 76.28%] at care sites and 73.24% [65.95% - 80.52%] at sites involved in preventing mother-to-child transmission (PMTCT sites). Potential predictors of HIV serodiscordance were: household head status; serostatus of last child; duration of relationship; multiple and occasional sexual partners; sharing serostatus with spouse; duration of couple relationship; spouse’s extramarital relationships and strained relations with children. 
  Conclusion: Response strategies against the HIV pandemic need to be reshaped to better supervise the follow-up of HIV serodiscordant couples in the city of Parakou specifically and in Benin in general.
 
</p></abstract><kwd-group><kwd>Serodiscordance</kwd><kwd> HIV</kwd><kwd> Prevalence</kwd><kwd> Associated Factors</kwd><kwd> Benin</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Human Immunodeficiency Virus (HIV) infection remains a major public health problem, responsible for over 36.3 million deaths worldwide to date [<xref ref-type="bibr" rid="scirp.129034-ref1">1</xref>] . Reducing sexual transmission of the virus, particularly among serodiscordant couples, is one of the most important challenges currently facing the fight against the pandemic. Worldwide, more than 50% of new HIV infections occur in serodiscordant couples, either because of a previous infection in one of the partners, or because of infidelity [<xref ref-type="bibr" rid="scirp.129034-ref2">2</xref>] . In many sub-Saharan African countries, a high proportion of people living with HIV are in long-term serodiscordant relationships; there are around 3% to 20% of discordant couples in the general population [<xref ref-type="bibr" rid="scirp.129034-ref3">3</xref>] . This phenomenon is increasingly recognized worldwide as a key factor in sustaining the HIV epidemic [<xref ref-type="bibr" rid="scirp.129034-ref4">4</xref>] . In Benin, the main strategies fighting against the epidemic are focused on vertical transmission and HIV serodiscordance within couples remains poorly documented. The production of data about this matter will help improve the response to achieve the goal of zero new infections by 2030.</p><p>Objective: The aim of this study was to shed light on HIV serodiscordance among infected couples in an urban area. More specifically, the aim was to measure the extent of the phenomenon by calculating prevalence and identifying potential predictors of serodiscordance in couples affected.</p></sec><sec id="s2"><title>2. Setting, Patients and Study Methods</title><sec id="s2_1"><title>2.1. Study Setting</title><p>The present study took place in the town of Parakou in north-eastern Benin. It was carried out on 23 prevention of mother-to-child transmission (PMTCT) sites and 7 care sites in the town, involved in the screening, care and/or follow-up of people living with HIV (PLHIV). Parakou is a cosmopolitan town located 415 km from the capital, Cotonou. The total population was estimated at 255,478 with a sex ratio of 0.99. Of this young population, 41.16% were children under the age of 15, while 51.97% were aged 18 and over. In 76% of cases, men were the head of household [<xref ref-type="bibr" rid="scirp.129034-ref5">5</xref>] . HIV seroprevalence was 0.4% in 2021 [<xref ref-type="bibr" rid="scirp.129034-ref6">6</xref>] .</p></sec><sec id="s2_2"><title>2.2. Patients and Study Method</title><p>This was a descriptive, analytic, cross-sectional study conducted over a 6-month period from July to December 2022. Participants were selected according to the following criteria: women or men aged 18 and over; living with HIV for at least 6 months; whose spouse’s status was known to health care services; in or having been in a stable union; received at one of the data collection sites during the study period and having given informed consent to the study. Patients physically or mentally unable to answer the questions and cases of withdrawal of consent were excluded from this study. We used non-probability sampling for convenience. The Schwartz minimum sample size was 345 subjects. Quantitative and qualitative data on participants’ lives were collected using a questionnaire, focusing on socio-demographic aspects, antecedents, behaviours, marital and psycho-social aspects presented by the participants. Clinical and therapeutic data were collected from patients’ personal records. The dependent variable, represented by serodiscordance within HIV+ couples, was defined as a couple in which one partner was HIV-infected and the other was not.</p><p>The data collected were analyzed using R 4.3.0 software. Quantitative variables were expressed as means with standard deviations, and qualitative variables as proportions. The Chi-square test was used to compare categorical variables with numbers &gt; 5, and the Fisher test for variables with numbers ≤ 5. The Student’s T-test was used to compare means. The association between the two variables was established for a value of p &lt; 0.05. A threshold of 20% was used to select variables for inclusion in a logistic regression model to identify potential predictors of HIV serodiscordance among infected couples in the city of Parakou.</p></sec></sec><sec id="s3"><title>3. Results</title><p>During the study period, 417 study subjects meeting the inclusion criteria were surveyed.</p><sec id="s3_1"><title>3.1. General Characteristics of Participants</title><p>The average age of respondents was 38.17 &#177; 10.25 years. Females were the most represented with a proportion of 79.62%, in other words, a sex ratio of 0.26. Most of the respondents (309 subjects, in other words. 74.11%) were married, and 83.69% of them were in an active relationship (married, cohabiting, couple). The average duration of the relationship was 130.75 &#177; 101.67 months. The minimum duration was 7 months and the maximum was 520 months. Monogamous unions were the most common, accounting for 67.87% of couples. The respondent was head of household among only 140 couples (33.57%). Nearly a third of the respondents in our study had a primary or secondary education (136 respondents, or 32.61% of the sample). The average income of the respondents was 38,349 F CFA &#177; 43,443 with extremes of 0 and 340,000F. The urban environment was the most represented (88.73% of cases, in other words. 370 respondents).</p><p>All subjects included in our study were infected with HIV1 (100% of cases). Liver serology was made on 357 respondents, in other words, 85.61% of cases. Of these, 37 (10.36%) were co-infected with HIV and viral hepatitis, including 9.52% with hepatitis B. Nearly one patient in eight (51, 12.23%) had a history of STI. During the study period, the last children of those surveyed were aged between 1 and 5 years in the majority of cases, 171 (44.65%). Their serological status, for those known, was negative in 95.29% of cases.</p><p>The vast majority of respondents (99.28%) were aware of at least one route of transmission and at least one means of HIV prevention. Among these routes of transmission, sexual and blood transmission were the most familiar to 410 (98.32%) and 312 (74.82%) respondents respectively. Vertical transmission was only known to 165 respondents, representing 39.57% of the total. As for known means of prevention, 387 (92.81%) knew about condoms, followed by abstinence (262 or 62.83%) and faithfulness (197 or 47.24%). Most of the PLHIV surveyed kept themselves informed about HIV, and 81.05% were actively researching the subject. The most common sources of information were health workers (84.61% of cases), television (40.53% of cases) and social networks (23.67% of cases).</p></sec><sec id="s3_2"><title>3.2. Prevalence of HIV Serodiscordance</title><p>The 417 subjects surveyed in our study included 299 who were involved in an HIV serodiscordant relationship, while 118 were in a couple with a serodiscordant positive partner. The prevalence of HIV serodiscordance among couples affected in the city of Parakou in 2022 was therefore 71.70% (IC95% [67.07 - 75.92]). It was 70.91% [65.54 - 76.28%] at PEC sites and 73.24% [65.95% - 80.52%] at PTME sites.</p></sec><sec id="s3_3"><title>3.3. Factors Associated with HIV Serodiscordance among Couples in Univariate Analysis</title><p>According to the results of our study, there is a statistically significant difference between HIV serodiscordance and:</p><p>● Socio-demographic variables: marital status and household head status (<xref ref-type="table" rid="table1">Table 1</xref>).</p><p>● Antecedents: duration of the couple’s relationship, serostatus of the last child and desire for (other) children (<xref ref-type="table" rid="table2">Table 2</xref>).</p><p>● None of the clinical or therapeutic variables studied in our study (<xref ref-type="table" rid="table3">Table 3</xref>).</p><p>● Behavioral variables: occasional sexual partnership, sharing of serostatus with spouse and spouse’s extra-marital relationships (<xref ref-type="table" rid="table4">Table 4</xref>).</p><p>● Social and marital variables: state of stress or anxiety and relationship outcome (<xref ref-type="table" rid="table5">Table 5</xref>).</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Association between socio-demographic variables and HIV serodiscordance among infected couples—Parakou, 2022</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >Seroconcordance n (%)</th><th align="center" valign="middle" >Serodiscordance n (%)</th><th align="center" valign="middle" >OR (IC95%)</th><th align="center" valign="middle" >p</th></tr></thead><tr><td align="center" valign="middle" >Age (years)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.118</td></tr><tr><td align="center" valign="middle" >[20 - 30[</td><td align="center" valign="middle" >19 (4.56)</td><td align="center" valign="middle" >70 (16.79)</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >[30 - 40[</td><td align="center" valign="middle" >46 (11.03)</td><td align="center" valign="middle" >114 (27.34)</td><td align="center" valign="middle" >0.67 (0.36 - 1.24)</td><td align="center" valign="middle" >0.204</td></tr><tr><td align="center" valign="middle" >[40 - 50[</td><td align="center" valign="middle" >30 (7.19)</td><td align="center" valign="middle" >80 (19.19)</td><td align="center" valign="middle" >0.72 (0.37 - 1.40)</td><td align="center" valign="middle" >0.336</td></tr><tr><td align="center" valign="middle" >[50 - 76]</td><td align="center" valign="middle" >23 (5.51)</td><td align="center" valign="middle" >35 (8.39)</td><td align="center" valign="middle" >0.41 (0.20 - 0.86)</td><td align="center" valign="middle" >0.018</td></tr><tr><td align="center" valign="middle" >Gender</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.599</td></tr><tr><td align="center" valign="middle" >Male</td><td align="center" valign="middle" >26 (6.24)</td><td align="center" valign="middle" >59 (14.15)</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Female</td><td align="center" valign="middle" >92 (22.06)</td><td align="center" valign="middle" >240 (57.55)</td><td align="center" valign="middle" >1.15 (0.68 - 1.93)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Marital status</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.007</td></tr><tr><td align="center" valign="middle" >Married</td><td align="center" valign="middle" >79 (18.94)</td><td align="center" valign="middle" >230 (55.16)</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Cohabiting</td><td align="center" valign="middle" >8 (1.92)</td><td align="center" valign="middle" >25 (5.99)</td><td align="center" valign="middle" >1.07 (0.46 - 2.48)</td><td align="center" valign="middle" >0.868</td></tr><tr><td align="center" valign="middle" >In couple</td><td align="center" valign="middle" >1 (0.24)</td><td align="center" valign="middle" >6 (1.44)</td><td align="center" valign="middle" >2.06 (0.24 - 17.38)</td><td align="center" valign="middle" >0.506</td></tr><tr><td align="center" valign="middle" >Divorced</td><td align="center" valign="middle" >13 (3.12)</td><td align="center" valign="middle" >26 (6.23)</td><td align="center" valign="middle" >0.69 (0.34 - 1.40)</td><td align="center" valign="middle" >0.302</td></tr><tr><td align="center" valign="middle" >Widowed</td><td align="center" valign="middle" >17 (4.08)</td><td align="center" valign="middle" >12 (2.88)</td><td align="center" valign="middle" >0.24 (0.11 - 0.53)</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >Education level</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.366</td></tr><tr><td align="center" valign="middle" >None</td><td align="center" valign="middle" >32 (7.67)</td><td align="center" valign="middle" >79 (18.95)</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Primary</td><td align="center" valign="middle" >44 (10.55)</td><td align="center" valign="middle" >92 (22.06)</td><td align="center" valign="middle" >0.85 (0.49 - 1.46)</td><td align="center" valign="middle" >0.551</td></tr><tr><td align="center" valign="middle" >Secondary</td><td align="center" valign="middle" >36 (8.63)</td><td align="center" valign="middle" >100 (23.98)</td><td align="center" valign="middle" >1.12 (0.64 - 1.97)</td><td align="center" valign="middle" >0.680</td></tr><tr><td align="center" valign="middle" >Higher</td><td align="center" valign="middle" >6 (1.44)</td><td align="center" valign="middle" >28 (6.72)</td><td align="center" valign="middle" >1.89 (0.71 - 5.00)</td><td align="center" valign="middle" >0.199</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Monthly revenue (CFA)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.476</td></tr><tr><td align="center" valign="middle" >[0 - 50,000[</td><td align="center" valign="middle" >86 (20.62)</td><td align="center" valign="middle" >229 (54.92)</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >[50,000 - 100,000[</td><td align="center" valign="middle" >19 (4.56)</td><td align="center" valign="middle" >48 (11.51)</td><td align="center" valign="middle" >0.95 (0.53 - 1.71)</td><td align="center" valign="middle" >0.860</td></tr><tr><td align="center" valign="middle" >[100,000 - 340,000[</td><td align="center" valign="middle" >13 (3.12)</td><td align="center" valign="middle" >22 (5.27)</td><td align="center" valign="middle" >0.64 (0.31 - 1.32)</td><td align="center" valign="middle" >0.223</td></tr><tr><td align="center" valign="middle" >Residence</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.559</td></tr><tr><td align="center" valign="middle" >Urban</td><td align="center" valign="middle" >103 (24.70)</td><td align="center" valign="middle" >267 (64.03)</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Rural</td><td align="center" valign="middle" >15 (3.60)</td><td align="center" valign="middle" >32 (7.67)</td><td align="center" valign="middle" >0.82 (0.43 - 1.58)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Household type</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.107</td></tr><tr><td align="center" valign="middle" >Monogamous</td><td align="center" valign="middle" >87 (20.86)</td><td align="center" valign="middle" >196 (47.00)</td><td align="center" valign="middle" >283 (67.87%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Polygamous</td><td align="center" valign="middle" >31 (7.44)</td><td align="center" valign="middle" >103 (24.70)</td><td align="center" valign="middle" >134 (32.13%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Head of household</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.001</td></tr><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >66 (15.83)</td><td align="center" valign="middle" >211 (50.60)</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >52 (12.47)</td><td align="center" valign="middle" >88 (21.10)</td><td align="center" valign="middle" >0.53 (0.34 - 0.82)</td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Relationship between respondent history and HIV serodiscordance in infected couples—Parakou, 2022</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >Seroconcordance n (%)</th><th align="center" valign="middle" >Serodiscordance n (%)</th><th align="center" valign="middle" >OR (IC95%)</th><th align="center" valign="middle" >P</th></tr></thead><tr><td align="center" valign="middle"  colspan="3"  >Viral hepatitis</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.503</td></tr><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >86 (20.62)</td><td align="center" valign="middle" >234 (56.11)</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >12 (2.88)</td><td align="center" valign="middle" >25 (6.00)</td><td align="center" valign="middle" >0.77 (0.37 - 1.59)</td><td align="center" valign="middle" >0.474</td></tr><tr><td align="center" valign="middle" >Not tested</td><td align="center" valign="middle" >20 (4.80)</td><td align="center" valign="middle" >40 (9.59)</td><td align="center" valign="middle" >0.73 (0.41 - 1.33)</td><td align="center" valign="middle" >0.307</td></tr><tr><td align="center" valign="middle"  colspan="2"  >History of STI<sup>a</sup></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.637</td></tr><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >105 (25.18)</td><td align="center" valign="middle" >261 (62.59)</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >13 (3.12)</td><td align="center" valign="middle" >38 (9.11)</td><td align="center" valign="middle" >1.18 (0.60 - 2.30)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  colspan="3"  >Duration of infection (years)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.925</td></tr><tr><td align="center" valign="middle" >&lt;1</td><td align="center" valign="middle" >15 (3.60)</td><td align="center" valign="middle" >38 (9.11)</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >[1 - 5[</td><td align="center" valign="middle" >50 (11.99)</td><td align="center" valign="middle" >136 (32.61)</td><td align="center" valign="middle" >1.07 (0.54 - 2.12)</td><td align="center" valign="middle" >0.838</td></tr><tr><td align="center" valign="middle" >[5 - 10[</td><td align="center" valign="middle" >31 (7.43)</td><td align="center" valign="middle" >70 (16.79)</td><td align="center" valign="middle" >0.89 (0.43 - 1.85)</td><td align="center" valign="middle" >0.758</td></tr><tr><td align="center" valign="middle" >≥10</td><td align="center" valign="middle" >22 (5.28)</td><td align="center" valign="middle" >55 (13.19)</td><td align="center" valign="middle" >0.99 (0.45 - 2.14)</td><td align="center" valign="middle" >0.973</td></tr><tr><td align="center" valign="middle"  colspan="4"  >Duration of relationship (months)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >[7 - 520]</td><td align="center" valign="middle"  colspan="3"  >(130.75 years &#177; 101.67)</td><td align="center" valign="middle" >0.004</td></tr><tr><td align="center" valign="middle"  colspan="3"  >Last child status (n = 361)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.005</td></tr><tr><td align="center" valign="middle" >Negative</td><td align="center" valign="middle" >93 (25.76)</td><td align="center" valign="middle" >251 (69.53)</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Positive</td><td align="center" valign="middle" >10 (2.77)</td><td align="center" valign="middle" >7 (1.94)</td><td align="center" valign="middle" >0.26 (0.10 - 0.70)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  colspan="4"  >Desire for (other) children</td><td align="center" valign="middle" >0.242</td></tr><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >45 (10.79)</td><td align="center" valign="middle" >96 (23.02)</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >73 (17.51)</td><td align="center" valign="middle" >203 (48.68)</td><td align="center" valign="middle" >1.30 (0.84 - 2.03)</td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>a: sexually transmitted infections.</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Association between respondents’ clinical and therapeutic variables and HIV serodiscordance among infected couples—Parakou, 2022</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >Seroconcordance n (%)</th><th align="center" valign="middle" >Serodiscordance n (%)</th><th align="center" valign="middle" >OR (IC95%)</th><th align="center" valign="middle" >p</th></tr></thead><tr><td align="center" valign="middle"  colspan="3"  >Clinical condition</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.549</td></tr><tr><td align="center" valign="middle" >Good</td><td align="center" valign="middle" >109 (26.14)</td><td align="center" valign="middle" >281 (67.39)</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Poor</td><td align="center" valign="middle" >9 (2.16)</td><td align="center" valign="middle" >18 (4.31)</td><td align="center" valign="middle" >0.78 (0.34 - 1.78)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  colspan="3"  >Clinical stage (WHO)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.714</td></tr><tr><td align="center" valign="middle" >Stage 1</td><td align="center" valign="middle" >92 (22.06)</td><td align="center" valign="middle" >239 (57.31)</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Stage 2</td><td align="center" valign="middle" >14 (3.36)</td><td align="center" valign="middle" >37 (8.87)</td><td align="center" valign="middle" >1.02 (0.54 - 1.97)</td><td align="center" valign="middle" >0.959</td></tr><tr><td align="center" valign="middle" >Stage 3 and 4</td><td align="center" valign="middle" >12 (2.88)</td><td align="center" valign="middle" >23 (5.52)</td><td align="center" valign="middle" >0.74 (0.35 - 1.54)</td><td align="center" valign="middle" >0.419</td></tr><tr><td align="center" valign="middle"  colspan="3"  >Circumstance of discovery of infection</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.158</td></tr><tr><td align="center" valign="middle" >PMTCT<sup>a</sup></td><td align="center" valign="middle" >56 (13.43)</td><td align="center" valign="middle" >152 (36.45)</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Hospital contact</td><td align="center" valign="middle" >38 (9.11)</td><td align="center" valign="middle" >78 (18.70)</td><td align="center" valign="middle" >0.75 (0.45 - 1.22)</td><td align="center" valign="middle" >0.247</td></tr><tr><td align="center" valign="middle" >Voluntary testing</td><td align="center" valign="middle" >20 (4.80)</td><td align="center" valign="middle" >66 (15.83)</td><td align="center" valign="middle" >01.23 (0.69 - 2.22)</td><td align="center" valign="middle" >0.481</td></tr><tr><td align="center" valign="middle" >Family screening</td><td align="center" valign="middle" >4 (0.96)</td><td align="center" valign="middle" >3 (0.72)</td><td align="center" valign="middle" >0.28 (0.06 - 1.27)</td><td align="center" valign="middle" >0.099</td></tr><tr><td align="center" valign="middle"  colspan="3"  >Viral load at last check-up</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.069</td></tr><tr><td align="center" valign="middle" >Detectable</td><td align="center" valign="middle" >28 (6.72)</td><td align="center" valign="middle" >48 (11.51)</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >undetectable</td><td align="center" valign="middle" >90 (21.58)</td><td align="center" valign="middle" >251 (60.19)</td><td align="center" valign="middle" >1.63 (0.96 - 2.75)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  colspan="2"  >ART compliance</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.337</td></tr><tr><td align="center" valign="middle" >Good</td><td align="center" valign="middle" >97 (23.26)</td><td align="center" valign="middle" >257 (61.63)</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Poor</td><td align="center" valign="middle" >21 (5.04)</td><td align="center" valign="middle" >42 (10.07)</td><td align="center" valign="middle" >1.32 (0.75 - 2.35)</td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>a: preventing mother-to-child transmission.</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Association between behavioral variables and HIV serodiscordance in infected couples—Parakou, 2022</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >Seroconcordance n (%)</th><th align="center" valign="middle" >Serodiscordance n (%)</th><th align="center" valign="middle" >OR (IC95%)</th><th align="center" valign="middle" >p</th></tr></thead><tr><td align="center" valign="middle"  colspan="3"  >Frequent condom use</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.037</td></tr><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >93 (22.30)</td><td align="center" valign="middle" >205 (49.16)</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >25 (6.00)</td><td align="center" valign="middle" >94 (22.54)</td><td align="center" valign="middle" >1.71 (1.03 - 2.83)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  colspan="3"  >Condom use at last intercourse</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.076</td></tr><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >98 (23.50)</td><td align="center" valign="middle" >224 (53.72)</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >20 (4.80)</td><td align="center" valign="middle" >75 (17.98)</td><td align="center" valign="middle" >1.64 (0.95 - 2.84)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  colspan="4"  >Multiple sexual partnerships</td><td align="center" valign="middle" >0.104</td></tr><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >101 (24.22)</td><td align="center" valign="middle" >235 (56.35)</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >17 (4.08)</td><td align="center" valign="middle" >64 (15.35)</td><td align="center" valign="middle" >1.62 (0.90 - 2.90)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  colspan="3"  >Occasional sexual partnerships</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >89 (21.35)</td><td align="center" valign="middle" >137 (32.85)</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >29 (6.95)</td><td align="center" valign="middle" >162 (38.85)</td><td align="center" valign="middle" >3.63 (2.25 - 5.85)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  colspan="3"  >Stable relationships since diagnosis</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.078</td></tr><tr><td align="center" valign="middle" >0 - 1</td><td align="center" valign="middle" >103 (24.70)</td><td align="center" valign="middle" >239 (57.31)</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >2 - 6</td><td align="center" valign="middle" >15 (3.60)</td><td align="center" valign="middle" >60 (14.39)</td><td align="center" valign="middle" >1.72 (0.94 - 3.18)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  colspan="3"  >Sharing serostatus with spouse</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >33 (7.91)</td><td align="center" valign="middle" >156 (37.41)</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >85 (20.38)</td><td align="center" valign="middle" >143 (34.30)</td><td align="center" valign="middle" >0.36 (0.22 - 0.57)</td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap></sec><sec id="s3_4"><title>3.4. Potential Predictors of HIV Serodiscordance among Infected Couples in the City of Parakou in 2022</title><p>The multivariate analysis model of this study shows that the potential predictors of serodiscordance were: the status of head of household, the serological status of</p><table-wrap id="table5" ><label><xref ref-type="table" rid="table5">Table 5</xref></label><caption><title> Association between variables relating to social and marital life and HIV serodiscordance among infected couples—Parakou, 2022</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >Seroconcordance n (%)</th><th align="center" valign="middle" >Serodiscordance n (%)</th><th align="center" valign="middle" >OR (IC95%)</th><th align="center" valign="middle" >p</th></tr></thead><tr><td align="center" valign="middle"  colspan="3"  >Tensions within the couple</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.428</td></tr><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >92 (22.06)</td><td align="center" valign="middle" >222 (54.24)</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >26 (6.24)</td><td align="center" valign="middle" >77 (18.46)</td><td align="center" valign="middle" >1.23 (0.74 - 2.04)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  colspan="3"  >Spouse’s attitude towards the disease</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >Hostile or indifferent</td><td align="center" valign="middle" >14 (6.14)</td><td align="center" valign="middle" >21 (9.21)</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Good</td><td align="center" valign="middle" >71 (31.14)</td><td align="center" valign="middle" >122 (53.51)</td><td align="center" valign="middle" >1.15 (0.55 - 2.39)</td><td align="center" valign="middle" >0.718</td></tr><tr><td align="center" valign="middle" >Uninformed</td><td align="center" valign="middle" >33 (7.91)</td><td align="center" valign="middle" >156 (37.41)</td><td align="center" valign="middle" >3.15 (1.45 - 6.83)</td><td align="center" valign="middle" >0.004</td></tr><tr><td align="center" valign="middle"  colspan="3"  >Partner involvement in disease monitoring</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >16 (3.84)</td><td align="center" valign="middle" >30 (7.19)</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >69 (16.55)</td><td align="center" valign="middle" >113 (27.10)</td><td align="center" valign="middle" >0.87 (0.44 - 1.72)</td><td align="center" valign="middle" >0.695</td></tr><tr><td align="center" valign="middle" >Not informed</td><td align="center" valign="middle" >33 (7.91)</td><td align="center" valign="middle" >156 (37.41)</td><td align="center" valign="middle" >2.52 (1.23 - 5.15)</td><td align="center" valign="middle" >0.011</td></tr><tr><td align="center" valign="middle"  colspan="3"  >Stress or anxiety</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.030</td></tr><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >87 (20.86)</td><td align="center" valign="middle" >187 (44.84)</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >31 (7.44)</td><td align="center" valign="middle" >112 (26.86)</td><td align="center" valign="middle" >1.68 (1.05 - 2.69)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  colspan="2"  >Tense relationships with children</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.057</td></tr><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >114 (27.34)</td><td align="center" valign="middle" >272 (65.23)</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >4 (0.96)</td><td align="center" valign="middle" >27 (6.47)</td><td align="center" valign="middle" >2.83 (0.97 - 8.27)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  colspan="2"  >Become relationship</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.001</td></tr><tr><td align="center" valign="middle" >Continuity</td><td align="center" valign="middle" >88 (21.10)</td><td align="center" valign="middle" >261 (62.59)</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Separation/divorce</td><td align="center" valign="middle" >13 (3.12)</td><td align="center" valign="middle" >26 (6.23)</td><td align="center" valign="middle" >0.67 (0.33 - 1.37)</td><td align="center" valign="middle" >0.276</td></tr><tr><td align="center" valign="middle" >Death of spouse</td><td align="center" valign="middle" >17 (4.08)</td><td align="center" valign="middle" >12 (2.88)</td><td align="center" valign="middle" >0.24 (0.11 - 0.52)</td><td align="center" valign="middle" >&lt;0.001</td></tr></tbody></table></table-wrap><p>the last child, the existence of multiple sexual partners, the existence of occasional sexual partners, the sharing of serological status with the spouse, the duration of the couple’s relationship, the spouse’s extra-marital relationships and strained relations with children (<xref ref-type="table" rid="table6">Table 6</xref>).</p></sec></sec><sec id="s4"><title>4. Discussion</title><sec id="s4_1"><title>4.1. Prevalence of HIV Serodiscordance</title><p>In our study, the prevalence of HIV serodiscordance was 71.70%. It was 73.24% at sites involved solely in monitoring pregnant women. This result corresponds to the model described by Chemaitelly H. [<xref ref-type="bibr" rid="scirp.129034-ref7">7</xref>] in 2012. According to the author, in countries with a low prevalence of HIV infection, around 75% of partnerships affected by HIV are discordant. Benin, with an HIV prevalence of around 1.2%, ranks among these low-prevalence countries. The prevalence described in our study is similar to that reported by Reed et al. [<xref ref-type="bibr" rid="scirp.129034-ref8">8</xref>] , in the African cohort study,</p><table-wrap id="table6" ><label><xref ref-type="table" rid="table6">Table 6</xref></label><caption><title> Potential predictors of HIV serodiscordance among infected couples in the city of Parakou in 2022</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >ORa (IC 95%)</th><th align="center" valign="middle" >p</th></tr></thead><tr><td align="center" valign="middle" >Head of household</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >0.25 (0.13 - 0.47)</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >Serological status of last child</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Negative</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Positive</td><td align="center" valign="middle" >0.14 (0.04 - 0.44)</td><td align="center" valign="middle" >0.001</td></tr><tr><td align="center" valign="middle" >Multiple sexual partners</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >2.91 (1.39 - 6.09)</td><td align="center" valign="middle" >0.005</td></tr><tr><td align="center" valign="middle" >Occasional sexual partners</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >7.17 (3.78 - 13.60)</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >Sharing status with spouse</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >0.31 (0.17 - 0.55)</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >Duration of relationship (in months)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >[7 - 272]</td><td align="center" valign="middle" >0.996 (0.993 - 0.999)</td><td align="center" valign="middle" >0.003</td></tr><tr><td align="center" valign="middle" >Spouse’s extra-marital relationships</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >0.51 (0.26 - 0.99)</td><td align="center" valign="middle" >0.048</td></tr><tr><td align="center" valign="middle" >Tense relationships with children</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >4.51 (1.35 - 15.09)</td><td align="center" valign="middle" >0.015</td></tr></tbody></table></table-wrap><p>which was 78.52%. Similarly, in Benin City, Nigeria, the reported prevalence varied between 77% and 78.8% [<xref ref-type="bibr" rid="scirp.129034-ref9">9</xref>] [<xref ref-type="bibr" rid="scirp.129034-ref10">10</xref>] .</p><p>In contrast, Ujah I. [<xref ref-type="bibr" rid="scirp.129034-ref11">11</xref>] in Lagos and Akani [<xref ref-type="bibr" rid="scirp.129034-ref12">12</xref>] at the University Hospital of Port Harcourt, reported lower prevalences, respectively 66.8% and 52%. In Nweni, south-east Nigeria, Ezeama [<xref ref-type="bibr" rid="scirp.129034-ref13">13</xref>] and Nwachukwu [<xref ref-type="bibr" rid="scirp.129034-ref14">14</xref>] found respective prevalences of 54.7% and 38.9% between 2014 and 2021.</p><p>This difference can be explained by variations in regional HIV prevalence rates in these countries, which may or may not limit the risk for a subject in the general population to couple up with an HIV-negative partner. While HIV seroprevalence in Lagos was estimated at 1.2% in 2021 [<xref ref-type="bibr" rid="scirp.129034-ref15">15</xref>] , it was several times higher in other cities: 7.3% in Port-Harcourt [<xref ref-type="bibr" rid="scirp.129034-ref16">16</xref>] ; 9.6% in Nw&#233;ni [<xref ref-type="bibr" rid="scirp.129034-ref13">13</xref>] .</p></sec><sec id="s4_2"><title>4.2. Factors Associated with HIV Serodiscordance</title><p>The multivariate analysis model of this study shows that the potential predictors of serodiscordance were the status of the head of household, the duration of the couple’s relationship, the serostatus of the last child, the existence of multiple sexual partners, the existence of occasional sexual partners, the sharing of serostatus with the spouse, the spouse’s extra-marital relationships and strained relations with children. In Congo, the explanatory factors for serodiscordance were: the number of partners, region of residence, number of children, length of union, age, level of education, ethnicity, protected sex, religion, standard of living and knowledge of HIV/AIDS transmission mechanisms, love and knowledge of infected partner’s serostatus [<xref ref-type="bibr" rid="scirp.129034-ref17">17</xref>] . In Mozambique, the factors found by Juga et al. [<xref ref-type="bibr" rid="scirp.129034-ref18">18</xref>] in 2020 included: HIV prevalence, number of unions for women, presence of STIs in men, condom use by women, wealth index, condom use by men and number of unions for men. In Nigeria, Akani [<xref ref-type="bibr" rid="scirp.129034-ref12">12</xref>] found the following associated factors: history of at least two ends of pregnancy (OR: 3.05; 95% CI: 2.91 - 3.89) and five or more sexual relationships in the course of a lifetime (OR: 2.3; 95% CI: 1.27 - 3.21).</p><sec id="s4_2_1"><title>4.2.1. Head of Household Status</title><p>In fact, the status of head of household is a protective factor for serodiscordance, multiplying the risk of being in a positive serodiscordant relationship by 4. This can be explained by the fact that the HIV-infected head of household can impose the type of sexuality he or she wishes on the couple, and decide whether or not to adopt transmission prevention strategies. In this context, the HIV-negative subject, who is in a “dominated” position, cannot negotiate the adoption of preventive measures to maintain his or her serological status, which increases the risk of transmission of the virus within the stable couple. This was reported by Sawadogo et al. [<xref ref-type="bibr" rid="scirp.129034-ref19">19</xref>] , in a study of unequal power relations within serodiscordant couples in Lom&#233;, Togo, in 2022. For the authors, the domination of male partners is acutely felt in the field of sexuality and prevention, notably through the coercion that can frame a male partner’s refusal to wear a condom by using his power of domination over his partner(s).</p></sec><sec id="s4_2_2"><title>4.2.2. Duration of Relationship</title><p>The average duration of the couple’s relationship was 130.75 &#177; 101.67 months, or around 10.11 &#177; 8.1 years. The group of couples with a longevity of between 10 and 20 years was the largest (30.21%), and 73.86% of couples had been together for at least 5 years. This is the same observation made by Diemer [<xref ref-type="bibr" rid="scirp.129034-ref20">20</xref>] , for whom the majority of couples had a longevity of over 5 years.</p><p>When the duration of the couple’s relationship increases by one month, the risk of serodiscordance decreases by around 1%. In other words, the longer the relationship lasts, the greater the risk of a positive seroconcordance. This may be explained by the fact that the longer the relationship lasts, the fewer preventive measures are observed, either by the initially positive partner, or by the initially negative partner, who may thus be contaminated inside or outside the couple as a result of lax preventive attention.</p></sec><sec id="s4_2_3"><title>4.2.3. Last Child’s Serostatus</title><p>The serostatus of the last child is a protective factor for HIV serodiscordance in couples affected by the infection. The probability of being in a serodiscordant relationship when the last child’s status is positive is reduced by 86%. The positive status of the last child exposes the mother 7 times more to a positive serodiscordant relationship than the negative serostatus of the last child.</p><p>This result could be explained by the low proportion of respondents who share their serostatus with their spouse. This undermines preventive efforts, notably ART for mother and infant, which cannot explain the prolonged use of long-term post-partum medication. In the town of Parakou, community organization is still the rule, and couples can count on unfailing social support to accompany the mother-child couple in the first few months of the child’s life. Under these conditions, if they do not share their serostatus with these community members, and to avoid arousing suspicion, mothers may be led to take risks that are detrimental to PMTCT (poor compliance with ART, prolonged breast-feeding, failure to keep follow-up appointments, etc.).</p></sec><sec id="s4_2_4"><title>4.2.4. Sharing Serostatus with Spouse/Partner</title><p>In our study, 54.68% of participants (n = 228) had shared their serostatus with their spouse. This corresponded to 67.06% of men (n = 57) and 51.51% of women (n = 171). While the intention to share one’s serostatus is high, as shown by Alassani et al. [<xref ref-type="bibr" rid="scirp.129034-ref21">21</xref>] in Parakou in 2020 with a proportion of 92.41%, actual sharing in the event of a positive result remains highly variable. Our result is similar to that described by Coutherut and Desclaux [<xref ref-type="bibr" rid="scirp.129034-ref22">22</xref>] in Senegal, which was 56.7%. It is low compared with that described by Yaya [<xref ref-type="bibr" rid="scirp.129034-ref23">23</xref>] in Sokod&#233;, Togo (60.9%); by Diemer [<xref ref-type="bibr" rid="scirp.129034-ref20">20</xref>] in Bangui (70.3%); by Kra [<xref ref-type="bibr" rid="scirp.129034-ref24">24</xref>] in Bouak&#233;, C&#244;te-d’Ivoire (79.2%) and by Kouanda et al. [<xref ref-type="bibr" rid="scirp.129034-ref25">25</xref>] in Burkina-Faso (81.4%).</p></sec><sec id="s4_2_5"><title>4.2.5. Occasional or Multiple Sexual Partners</title><p>Having occasional or multiple sexual partners is a risk factor for HIV serodiscordance. This multiplies the risk of being in a discordant relationship by 7.17 and 2.91 respectively for subjects with occasional or multiple partners compared with those without.</p><p>The impact of multiple sexual partnerships on HIV transmission has been recognized for many years. In a low-prevalence country like Benin, the risk of contracting the infection is high, and so is the risk of ending up in a serodiscordant union.</p></sec></sec></sec><sec id="s5"><title>5. Conclusion</title><p>HIV serodiscordance is a significant phenomenon among infected couples in the city of Parakou in 2022. Nearly three out of four couples are affected. This makes it an important factor to take into account in strategies to fight the pandemic. The associated factors are multiple and linked to background, conjugal or social life and behavior. Current prevention strategies, which focus on pregnant women and young people, now need to pay particular attention to serodiscordant couples. The production of general data on the subject of HIV serodiscordance will provide a better overview of the phenomenon and enable us to reorient our strategies, if necessary, in order to achieve the ambitious goal of defeating HIV/AIDS by 2030.</p></sec><sec id="s6"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest regarding the publication of this paper.</p></sec><sec id="s7"><title>Cite this paper</title><p>Djossou, S.E.E., Sossa, J.C., Damien, G.B., Ahanhanzo-Gl&#232;l&#232;, R., Tokpanoud&#233;, C.N.I., Agballa, G., Nouatin, A.V., Ata&#239;gba I.N.E., Dettin, E. and Aguemon, B. (2023) Prevalence and Factors Associated with HIV Serodiscordance among Infected Couples in the City of Parakou (Benin). Open Journal of Internal Medicine, 13, 351-363. https://doi.org/10.4236/ojim.2023.134031</p></sec></body><back><ref-list><title>References</title><ref id="scirp.129034-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Développement et Santé (2010) VIH: Quelques Rappels d’épidémiologie. https://devsante.org/articles/vih-quelques-rappels-d-epidemiologie/</mixed-citation></ref><ref id="scirp.129034-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Développement et Santé (2011) Sérodiscordance et Désir d’enfant. https://devsante.org/actualites/serodiscordance-et-desir-d-enfant/</mixed-citation></ref><ref id="scirp.129034-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Rispel, L.C., Cloete, A., Metcalf, C.A., Moody, K. and Caswell, G. (2012) “Le [VIH] Fait Partie de la Relation”: Exploration de la Communication entre les Couples Sérodiscordants pour le VIH en Afrique du Sud et en Tanzanie. Culture, Health &amp; Sexuality, 14, 257-268. https://doi.org/10.1080/13691058.2011.621448</mixed-citation></ref><ref id="scirp.129034-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Persson, A. (2013) Notes sur les Concepts de “Sérodiscordance” et de “Risque” Dans les Couples ayant un Statut VIH Mixte. Global Public Health, 8, 209-220. https://doi.org/10.1080/17441692.2012.729219</mixed-citation></ref><ref id="scirp.129034-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Institut National de la Statistique et de la Démographie (2023) INStaD-Statistiques Démographiques. https://instad.bj/statistiques/statistiques-demographiques#nos-12-departements</mixed-citation></ref><ref id="scirp.129034-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Conseil National de Lutte Contre le Vih/Sida, La Tuberculose, Le Paludisme, les Hepatites, Les IST et les Epidemies (CNLS-TP) (2020) Rapport sur le Suivi Mondial de la Lutte contre le Sida 2020.</mixed-citation></ref><ref id="scirp.129034-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Chemaitelly, H., Cremin, I., Shelton, J., Hallett, T.B. and Abu-Raddad, L.J. (2012) Modèles Distincts de Discordance du VIH Selon la Taille De l’épidémie Dans Les Relations Sexuelles Stables en Afrique Subsaharienne. Sexually Transmitted Infections, 88, 51-57. https://doi.org/10.1136/sextrans-2011-050114</mixed-citation></ref><ref id="scirp.129034-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Reed, D.M., Esber, A.L., Crowell, T.A., Ganesan, K., Kibuuka, H., Maswai, J., et al. (2021) Les Personnes Vivant Avec le VIH Dans Des Partenariats Sérodiscordants Bénéficient d’un Meilleur Engagement Dans les Soins du VIH par Rapport aux personnes vivant avec le VIH dans des partenariats séroconcordants: Une analyse transversale de quatre pays africains. AIDS Research and Therapy, 18, 43.</mixed-citation></ref><ref id="scirp.129034-ref9"><label>9</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sagay</surname><given-names> A.S.</given-names></name>,<name name-style="western"><surname> Onakewhor</surname><given-names> J.</given-names></name>,<name name-style="western"><surname> Galadanci</surname><given-names> H. and Emuveyan </given-names></name>,<etal>et al</etal>. (<year>2006</year>)<article-title>HIV Status of Partners of HIV Positive Pregnant Women in Different Regions of Nigeria: Matters Arising</article-title><source> African Journal of Medicine and Medical Sciences</source><volume> 35</volume>,<fpage> 125</fpage>-<lpage>129</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.129034-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Onakewhor, J.U.E. and Erhabor, O.J. (2006) Prevalence of HIV Sero-Discordance in a Resource-Constraint Country. Sahel Medical Journal, 9, 46-51.</mixed-citation></ref><ref id="scirp.129034-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Ujah, I.A.O., Ezechi, O.C. and Ohihoin, A.G. (2015) Discordance du statut VIH: Facteurs Associés Chez les Femmes Enceintes Séropositives à Lagos, Dans le sudouest du Nigéria. African Journal of Reproductive Health, 19, 108-116.</mixed-citation></ref><ref id="scirp.129034-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Akani, C.I., Erhabor, O., Opurum, H., Ejele, O.A. and Nwauche, C.A. (2005) HIV Sero-Discordance among Nigerian Couples: Challenges and Controversies. Nigerian Medical Practitioner, 48, 62-66. https://doi.org/10.4314/nmp.v48i3.28766</mixed-citation></ref><ref id="scirp.129034-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Ezeama, C.O., Eleje, G.U., Okonkwo, T. and Ikechebelu, J.I. (2014) Partner Human Immunodeficiency Virus Sero-Discordance in Nnewi, Nigeria. Journal of HIV and Human Reproduction, 2, 2. https://doi.org/10.4103/2321-9157.135741</mixed-citation></ref><ref id="scirp.129034-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Nwachukwu, E.O., Ofiaeli, C.I., Agada, O., Nwankwo, O.K. and Njoku, I.E. (2021) Partner HIV Status Disclosure and Serodiscordant Couples Rates among Infected Adults in an Urban Community in South-East Nigeria: A Cross-Sectional Study. International Journal of Scientific Research in Dental and Medical Sciences, 3, 55-60.</mixed-citation></ref><ref id="scirp.129034-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">UNAIDS (2023). https://fasttrackcitiesmap.unaids.org/wp-content/uploads/2021/04/Lagos-City-Profile-1.pdf</mixed-citation></ref><ref id="scirp.129034-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Akani, C.I., Ojule, A.C., Opurum, H.C. and John, C.T. (2006) Sero-Prevalence of HIV Antibodies in Pregnant Women in Port Harcourt, Nigeria. Nigerian Journal of Medicine, 15, 44-48. https://doi.org/10.4314/njm.v15i1.37114</mixed-citation></ref><ref id="scirp.129034-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Gokaba, J.M. (2020) Sérologie discordante du VIH/sida et vie des couples en République du Congo: Profil sociodémographique, Comportements, Facteurs de survie et prise en charge. https://theses.hal.science/tel-03160588</mixed-citation></ref><ref id="scirp.129034-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Juga, A.J.C., Hens, N., Osman, N. and Aerts, M. (2020) Factors Associated with HIV Serodiscordance among Couples in Mozambique: Comparison of the 2009 INSIDA and 2015 IMASIDA Surveys. PLOS ONE, 15, e0234723. https://doi.org/10.1371/journal.pone.0234723</mixed-citation></ref><ref id="scirp.129034-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Sawadogo, N. and Djakpa, Y. (2022) Impact des rapports de pouvoir inégalitaires sur les difficultés de prévention du VIH au sein des couples sérodifférents à Lomé (Togo). https://www.rass-pgpa.org/wp-content/uploads/2022/11/TAP-15.pdf</mixed-citation></ref><ref id="scirp.129034-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Diemer, S.C.H., Longo, J.D., Tekpa, G., Gaunefet, C.E. and Ngbale, R.N. (2018) Facteurs Associés à la Divulgation du Statut de Séropositivité au VIH à Bangui. Sante Publique (Bucur), 30, 397-403. https://doi.org/10.3917/spub.183.0397</mixed-citation></ref><ref id="scirp.129034-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Alassani, A., Cissé, I.M., Imorou, R.S., Gomina, M., SakeAlassan, K., Codjo, L., et al. (2020) Déterminants du Dépistage Volontaire, Du Partage du Statut Sérologique et Prévalence de l’Infection VIH chez les Gestantes Suivis à Parakou. Revue Malienne d’Infectiologie et de Microbiologie, 15, 38-42. https://doi.org/10.53597/remim.v15i2.1730</mixed-citation></ref><ref id="scirp.129034-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Coutherut, J. and Desclaux, A. (2012) Le partage du Statut Sérologique avec l’Entourage: Taverne B., Desclaux A., Sow P. S., Delaporte E., Ndoye I. Evaluation de l’Impact Bioclinique et Social, Individuel et Collectif, du Traitement ARV Chez des Patients VIH-1 Pris en Charge Depuis 10 ans dans le cadre de l’ISAARV-Cohorte ANRS 1215. Rapport Final.</mixed-citation></ref><ref id="scirp.129034-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Yaya, I., Saka, B., Landoh, D.E., Patchali, M.P., Aboubakari, S.A., Makawa, M.S., et al. (2016) CO 15: Partage du Statut Sérologique au Partenaire Sexuel chez les Personnes Vivant avec le VIH sous Traitement Antirétroviral au CHR de Sokodé, Togo. Annales de Dermatologie et de Vénéréologie, 143, S26. https://doi.org/10.1016/S0151-9638(16)30142-9</mixed-citation></ref><ref id="scirp.129034-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Kra, K.O., Aba, A., Effi-Angbo, A.O., Koné, K.D. and Kadiané, K.N.J. (2014) A-21: Les Raisons du non Partage du Statut Sérologique chez les Personnes Vivant avec le VIH en Afrique Noire. Médecine et Maladies Infectieuses, 44, 24. https://doi.org/10.1016/S0399-077X(14)70104-0</mixed-citation></ref><ref id="scirp.129034-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Kouanda, S., Yaméogo, W.M.E., Berthé, A., Bila, B., Bocoum Yaya, F.K. and Somda, A. (2012) Partage de l’Information sur le Statut Sérologique VIH Positif: Facteurs Associés et Conséquences pour les Personnes Vivant avec le VIH/Sida au Burkina Faso. Revue d’Epidémiologie et de Santé Publique, 60, 221-228. https://doi.org/10.1016/j.respe.2011.12.135</mixed-citation></ref></ref-list></back></article>